The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models

Cytokine and Growth Factor Reviews

Volumn 16, Issue 4-5, 2005, Pages 407-420

  Yakar, Shoshana ^a   LeRoith, Derek ^a   Brodt, Pnina ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cancer; Insulin like growth factor; Mouse models; Receptor

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; LIGAND; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

BIOAVAILABILITY; BODY GROWTH; CALORIC RESTRICTION; CANCER CELL; CANCER MODEL; CANCER THERAPY; CARCINOGENESIS; DEVELOPMENT; DISEASE COURSE; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GROWTH; HUMAN; LIGAND BINDING; NONHUMAN; PHYSICAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BLOCKING; RECEPTOR GENE; REVIEW; TUMOR GROWTH;

ANIMALS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MODELS, ANIMAL; NEOPLASMS; RECEPTOR, IGF TYPE 1;

ANIMALIA;

EID: 22544461679     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2005.01.010     Document Type: Review

References (154)

1. D. Le Roith, C. Bondy, S. Yakar, J.L. Liu, and A. Butler The somatomedin hypothesis Endocr Rev 22 2001 53 74
2. C. Sell Caloric restriction and insulin-like growth factors in aging and cancer Horm Metab Res 35 2003 705 711
3. D. LeRoith, and C.T. Roberts Jr. The insulin-like growth factor system and cancer Cancer Lett 195 2003 127 137
4. S. Banerjee, A. Smallwood, S. Lamond, S. Campbell, and G. Nargund Igf2/H19 imprinting control region (ICR): an insulator or a position-dependent silencer? Sci World J 1 2001 218 224
5. K. Pavelic, D. Bukovic, and J. Pavelic The role of insulin-like growth factor 2 and its receptors in human tumors Mol Med 8 2002 771 780
6. W. Reik, K. Davies, W. Dean, G. Kelsey, and M. Constancia Imprinted genes and the coordination of fetal and postnatal growth in mammals Novartis Found Symp 237 2001 19 31 [discussion, pp. 31-42]
7. A. Nandi, Y. Kitamura, C.R. Kahn, and D. Accili Mouse models of insulin resistance Physiol Rev 84 2004 623 647
8. S.M. Firth, and R.C. Baxter Cellular actions of the insulin-like growth factor binding proteins Endocr Rev 23 2002 824 854
9. Y. Zhou, B.C. Xu, and H.G. Maheshwari A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse) Proc Natl Acad Sci USA 94 1997 13215 13220
10. J.L. Liu, A. Grinberg, and H. Westphal Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice Mol Endocrinol 12 1998 1452 1462
11. J. Baker, J.P. Liu, E.J. Robertson, and A. Efstratiadis Role of insulin-like growth factors in embryonic and postnatal growth Cell 75 1993 73 82
12. L. Powell-Braxton, P. Hollingshead, and C. Warburton IGF-I is required for normal embryonic growth in mice Genes Dev 7 1993 2609 2617
13. J.P. Liu, J. Baker, A.S. Perkins, E.J. Robertson, and A. Efstratiadis Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) Cell 75 1993 59 72
14. W.D. Salmon Jr., and W.H. Daughaday A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro J Lab Clin Med 49 1957 825 826
15. S. Yakar, J.L. Liu, and B. Stannard Normal growth and development in the absence of hepatic insulin-like growth factor I Proc Natl Acad Sci USA 96 1999 7324 7329
16. S. Yakar, C.J. Rosen, and W.G. Beamer Circulating levels of IGF-1 directly regulate bone growth and density J Clin Invest 110 2002 771 781
17. E. Gay, D. Seurin, S. Babajko, S. Doublier, M. Cazillis, and M. Binoux Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: repercussions on reproduction, ante- and perinatal mortality and postnatal growth Endocrinology 138 1997 2937 2947
18. A.J. D'Ercole, Z. Dai, and Y. Xing Brain growth retardation due to the expression of human insulin like growth factor binding protein-1 in transgenic mice: an in vivo model for the analysis of igf function in the brain. Brain Res Dev Brain Res 82 1994 213 222
19. Z. Dai, Y. Xing, C.M. Boney, D.R. Clemmons, and A.J. D'Ercole Human insulin-like growth factor-binding protein-1 (hIGFBP-1) in transgenic mice: characterization and insights into the regulation of IGFBP-1 expression Endocrinology 135 1994 1316 1327
20. H. Huang, K. Rajkumar, and L.J. Murphy Expression of insulin-like growth factor binding proteins (IGFBPs) in IGFBP-1 transgenic mice J Endocrinol 152 1997 99 108
21. K. Rajkumar, D. Barron, M.S. Lewitt, and L.J. Murphy Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice Endocrinology 136 1995 4029 4034
22. A. Hoeflich, M. Wu, and S. Mohan Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain Endocrinology 140 1999 5488 5496
23. L.J. Murphy, P. Molnar, X. Lu, and H. Huang Expression of human insulin-like growth factor-binding protein-3 in transgenic mice J Mol Endocrinol 15 1995 293 303
24. M.N. Pollak, E.S. Schernhammer, and S.E. Hankinson Insulin-like growth factors and neoplasia Nat Rev Cancer 4 2004 505 518
25. A. Juul, K. Main, W.F. Blum, J. Lindholm, M.B. Ranke, and N.E. Skakkebaek The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients Clin Endocrinol (Oxf) 41 1994 85 93
26. B.L. Stavola, R. Hardy, D. Kuh, I.S. Silva, M. Wadsworth, and A.J. Swerdlow Birthweight, childhood growth and risk of breast cancer in a British cohort Br J Cancer 83 2000 964 968
27. V.A. McCormack, I. dos Santos Silva, B.L. De Stavola, R. Mohsen, D.A. Leon, and H.O. Lithell Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort BMJ 326 2003 248
28. M.S. Sandhu, R. Luben, N.E. Day, and K.T. Khaw Self-reported birth weight and subsequent risk of colorectal cancer Cancer Epidemiol Biomarkers Prev 11 2002 935 938
29. G. Tibblin, M. Eriksson, S. Cnattingius, and A. Ekbom High birthweight as a predictor of prostate cancer risk Epidemiology 6 1995 423 424
30. J. Von Behren, and P. Reynolds Birth characteristics and brain cancers in young children Int J Epidemiol 32 2003 248 256
31. J.P. Thissen, J.M. Ketelslegers, and L.E. Underwood Nutritional regulation of the insulin-like growth factors Endocr Rev 15 1994 80 101
32. D. Albanes Total calories, body weight, and tumor incidence in mice Cancer Res 47 1987 1987 1992
33. B.A. Ruggeri, D.M. Klurfeld, D. Kritchevsky, and R.W. Furlanetto Growth factor binding to 7,12-dimethylbenz(a)anthracene-induced mammary tumors from rats subject to chronic caloric restriction Cancer Res 49 1989 4135 4141
34. S.E. Dunn, F.W. Kari, and J. French Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice Cancer Res 57 1997 4667 4672
35. X.F. Yang, W.G. Beamer, H. Huynh, and M. Pollak Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation Cancer Res 56 1996 1509 1511
36. K. Deitel, D. Dantzer, and P. Ferguson Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation J Surg Oncol 81 2002 75 79
37. M.M. Ramsey, R.L. Ingram, and A.B. Cashion Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis Endocrinology 143 2002 4139 4142
38. S.M. Swanson, and T.G. Unterman The growth hormone-deficient spontaneous dwarf rat is resistant to chemically induced mammary carcinogenesis Carcinogenesis 23 2002 977 982
39. N.Y. Chen, W.Y. Chen, L.J. Striker, G.E. Striker, and J.J. Kopchick Co-expression of bovine growth hormone (GH) and human GH antagonist genes in transgenic mice Endocrinology 138 1997 851 854
40. M. Pollak, M.J. Blouin, J.C. Zhang, and J.J. Kopchick Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist Br J Cancer 85 2001 428 430
41. J. Tornell, B. Carlsson, P. Pohjanen, H. Wennbo, L. Rymo, and O. Isaksson High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice J Steroid Biochem Mol Biol 43 1992 237 242
42. J. Tornell, L. Rymo, and O.G. Isaksson Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice Int J Cancer 49 1991 114 117
43. J. DiGiovanni, D.K. Bol, and E. Wilker Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion Cancer Res 60 2000 1561 1570
44. R.A. Moorehead, O.H. Sanchez, R.M. Baldwin, and R. Khokha Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma Oncogene 22 2003 853 857
45. J.A. Toretsky, and L.J. Helman Involvement of IGF-II in human cancer J Endocrinol 149 1996 367 372
46. Y. Wu, S. Yakar, L. Zhao, L. Hennighausen, and D. LeRoith Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis Cancer Res 62 2002 1030 1035
47. Y. Wu, K. Cui, and K. Miyoshi Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors Cancer Res 63 2003 4384 4388
48. C. Sell, M. Rubini, R. Rubin, J.P. Liu, A. Efstratiadis, and R. Baserga Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor Proc Natl Acad Sci USA 90 1993 11217 11221
49. C. Sell, G. Dumenil, and C. Deveaud Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts Mol Cell Biol 14 1994 3604 3612
50. A. Morrione, T. DeAngelis, and R. Baserga Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes J Virol 69 1995 5300 5303
51. R. Baserga The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55 1995 249 252
52. T. DeAngelis, A. Ferber, and R. Baserga Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor J Cell Physiol 164 1995 214 221
53. A. Lassak, L. Del Valle, and F. Peruzzi Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen J Biol Chem 277 2002 17231 17238
54. M. Prisco, F. Santini, and R. Baffa Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor J Biol Chem 277 2002 32078 32085
55. X. Tu, P. Batta, and N. Innocent Nuclear translocation of insulin receptor substrate-1 by oncogenes and Igf-I. Effect on ribosomal RNA synthesis J Biol Chem 277 2002 44357 44365
56. J.M. Boylan, and P.A. Gruppuso Insulin receptor substrate-1 is present in hepatocyte nuclei from intact rats Endocrinology 143 2002 4178 4183
57. H. Sun, X. Tu, M. Prisco, A. Wu, I. Casiburi, and R. Baserga Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2 Mol Endocrinol 17 2003 472 486
58. A. Wu, L. Sciacca, and R. Baserga Nuclear translocation of insulin receptor substrate-1 by the insulin receptor in mouse embryo fibroblasts J Cell Physiol 195 2003 453 460
59. H. Werner, E. Karnieli, F.J. Rauscher, and D. LeRoith Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene Proc Natl Acad Sci USA 93 1996 8318 8323
60. H. Werner, G.G. Re, and I.A. Drummond Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product Proc Natl Acad Sci USA 90 1993 5828 5832
61. H. Werner, and D. Le Roith The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis Crit Rev Oncog 8 1997 71 92
62. L. Girnita, A. Girnita, and B. Brodin Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact Cancer Res 60 2000 5278 5283
63. S. Abramovitch, T. Glaser, T. Ouchi, and H. Werner BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene FEBS Lett 541 2003 149 154
64. S. Abramovitch, and H. Werner Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene Horm Metab Res 35 2003 758 762
65. S.B. Maor, S. Abramovitch, M.R. Erdos, L.C. Brody, and H. Werner BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1 Mol Genet Metab 69 2000 130 136
66. S. Tanno, Y. Mitsuuchi, D.A. Altomare, G.H. Xiao, and J.R. Testa AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells Cancer Res 61 2001 589 593
67. H. Zhao, J. Dupont, S. Yakar, M. Karas, and D. LeRoith PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells Oncogene 23 2004 786 794
68. M. Elchebly, P. Payette, and E. Michaliszyn Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene Science 283 1999 1544 1548
69. J.M. Zabolotny, Y.B. Kim, and O.D. Peroni Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance Proc Natl Acad Sci USA 98 2001 5187 5192
70. L.A. Maile, and D.R. Clemmons The alphaVbeta3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor Endocrinology 143 2002 4259 4264
71. T. Sasaoka, K. Kikuchi, and T. Wada Dual role of SRC homology domain 2-containing inositol phosphatase 2 in the regulation of platelet-derived growth factor and insulin-like growth factor I signaling in rat vascular smooth muscle cells Endocrinology 144 2003 4204 4214
72. Y. Jiang, J.L. Chan, C.S. Zong, and L.H. Wang Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor J Biol Chem 271 1996 160 167
73. H. Kato, T.N. Faria, B. Stannard, C.T. Roberts Jr., and D. LeRoith Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3) J Biol Chem 268 1993 2655 2661
74. V.A. Blakesley, T. Kalebic, and L.J. Helman Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor Endocrinology 137 1996 410 417
75. C. Hernandez-Sanchez, V. Blakesley, T. Kalebic, L. Helman, and D. LeRoith The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis J Biol Chem 270 1995 29176 29181
76. A. Hongo, C. D'Ambrosio, M. Miura, A. Morrione, and R. Baserga Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor Oncogene 12 1996 1231 1238
77. H. Kato, T.N. Faria, B. Stannard, C.T. Roberts Jr., and D. LeRoith Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action Mol Endocrinol 8 1994 40 50
78. P. Brodt, L. Fallavollita, A.M. Khatib, A.A. Samani, and D. Zhang Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit J Biol Chem 276 2001 33608 33615
79. M. Rotsch, M. Maasberg, C. Erbil, G. Jaques, U. Worsch, and K. Havemann Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines J Cancer Res Clin Oncol 118 1992 502 508
80. F. Zia, S. Jacobs, F. Kull Jr., F. Cuttitta, J.L. Mulshine, and T.W. Moody Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo J Cell Biochem Suppl 24 1996 269 275
81. Y. Nakanishi, J.L. Mulshine, and P.G. Kasprzyk Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro J Clin Invest 82 1988 354 359
82. M. Parrizas, A.R. Saltiel, and D. LeRoith Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways J Biol Chem 272 1997 154 161
83. J.R. Singleton, A.E. Randolph, and E.L. Feldman Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis Cancer Res 56 1996 4522 4529
84. L. Long, R. Rubin, R. Baserga, and P. Brodt Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor Cancer Res 55 1995 1006 1009
85. A.A. Samani, E. Chevet, L. Fallavollita, J. Galipeau, and P. Brodt Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor Cancer Res 64 2004 3380 3385
86. M.K. Tennant, J.B. Thrasher, P.A. Twomey, R.H. Drivdahl, R.S. Birnbaum, and S.R. Plymate Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium J Clin Endocrinol Metab 81 1996 3774 3782
87. P.J. Kaplan, S. Mohan, P. Cohen, B.A. Foster, and N.M. Greenberg The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model Cancer Res 59 1999 2203 2209
88. A. Chott, Z. Sun, and D. Morganstern Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor Am J Pathol 155 1999 1271 1279
89. P. Burfeind, C.L. Chernicky, F. Rininsland, and J. Ilan Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo Proc Natl Acad Sci USA 93 1996 7263 7268
90. K. Reiss, C. D'Ambrosio, X. Tu, C. Tu, and R. Baserga Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect Clin Cancer Res 4 1998 2647 2655
91. T. Lopez, and D. Hanahan Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis Cancer Cell 1 2002 339 353
92. P.A. Kiely, A. Sant, and R. O'Connor RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death J Biol Chem 277 2002 22581 22589
93. U. Hermanto, C.S. Zong, W. Li, and L.H. Wang RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix Mol Cell Biol 22 2002 2345 2365
94. P. Delafontaine, Y.H. Song, and Y. Li Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels Arterioscler Thromb Vasc Biol 24 2004 435 444
95. Y. Tang, D. Zhang, L. Fallavollita, and P. Brodt Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor Cancer Res 63 2003 1166 1171
96. D. Zhang, A.A. Samani, and P. Brodt The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis Horm Metab Res 35 2003 802 808
97. G. Milazzo, F. Giorgino, and G. Damante Insulin receptor expression and function in human breast cancer cell lines Cancer Res 52 1992 3924 3930
98. L. Frittitta, L. Sciacca, and R. Catalfamo Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis? Cancer 85 1999 492 498
99. E.P. Beck, P. Russo, and B. Gliozzo Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue Gynecol Oncol 53 1994 196 201
100. L. Sciacca, A. Costantino, and G. Pandini Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism Oncogene 18 1999 2471 2479
101. G. Pandini, R. Vigneri, and A. Costantino Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling Clin Cancer Res 5 1999 1935 1944
102. A. Belfiore, G. Pandini, V. Vella, S. Squatrito, and R. Vigneri Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer Biochimie 81 1999 403 407
103. V. Papa, B. Gliozzo, and G.M. Clark Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer Cancer Res 53 1993 3736 3740
104. G. Pandini, F. Frasca, R. Mineo, L. Sciacca, R. Vigneri, and A. Belfiore Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved J Biol Chem 277 2002 39684 39695
105. R.W. Furlanetto, S.E. Harwell, and R.B. Baggs Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice Cancer Res 53 1993 2522 2526
106. L. Kanter-Lewensohn, A. Dricu, M. Wang, J. Wejde, R. Kiessling, and O. Larsson Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target Melanoma Res 8 1998 389 397
107. H. Lahm, P. Amstad, and J. Wyniger Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop Int J Cancer 58 1994 452 459
108. K. Scotlandi, S. Benini, and P. Nanni Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice Cancer Res 58 1998 4127 4131
109. C.L. Arteaga, L.J. Kitten, and E.B. Coronado Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice J Clin Invest 84 1989 1418 1423
110. S.L. Li, S.J. Liang, N. Guo, A.M. Wu, and Y. Fujita-Yamaguchi Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth Cancer Immunol Immunother 49 2000 243 252
111. D. Sachdev, S.L. Li, J.S. Hartell, Y. Fujita-Yamaguchi, J.S. Miller, and D. Yee A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I Cancer Res 63 2003 627 635
112. E.K. Maloney, J.L. McLaughlin, and N.E. Dagdigian An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation Cancer Res 63 2003 5073 5083
113. D. Burtrum, Z. Zhu, and D. Lu A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63 2003 8912 8921
114. L. Goetsch, A. Gonzalez, and O. Leger A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts Int J Cancer 113 2005 316 328
115. D. Yee, C.L. Van Den Berg, T.W. Kozelsky, J.G. Kuhn, and G.N. Cox Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice Biomed Pharmacother 50 1996 154 157
116. C.L. Van den Berg, G.N. Cox, and C.A. Stroh Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice Eur J Cancer 33 1997 1108 1113
117. D. Sachdev, J.S. Hartell, A.V. Lee, X. Zhang, and D. Yee A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells J Biol Chem 279 2004 5017 5024
118. S.E. Dunn, M. Ehrlich, and N.J. Sharp A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer Cancer Res 58 1998 3353 3361
119. W. Abramovits, and A.K. Gupta New therapy update: enbrel (etanercept) Skinmed 3 2004 333 335
120. E.K. Bergsland Update on clinical trials targeting vascular endothelial growth factor in cancer Am J Health Syst Pharm 61 2004 S12 S20
121. P.L. Lip, S. Chatterjee, and G.J. Caine Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade Br J Ophthalmol 88 2004 1543 1546
122. P. Hayry, M. Myllarniemi, and E. Aavik Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat FASEB J 9 1995 1336 1344
123. Z. Pietrzkowski, G. Mulholland, L. Gomella, B.A. Jameson, D. Wernicke, and R. Baserga Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1 Cancer Res 53 1993 1102 1106
124. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors Cancer Cell 5 2004 221 230
125. R. Baserga, F. Peruzzi, and K. Reiss The IGF-1 receptor in cancer biology Int J Cancer 107 2003 873 877
126. E. Surmacz Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor Oncogene 22 2003 6589 6597
127. G.S. Warshamana-Greene, J. Litz, E. Buchdunger, F. Hofmann, C. Garcia-Echeverria, and G.W. Krystal The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling Mol Cancer Ther 3 2004 527 535
128. D. Vasilcanu, A. Girnita, L. Girnita, R. Vasilcanu, M. Axelson, and O. Larsson The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway Oncogene 23 2004 7854 7862
129. G. Blum, A. Gazit, and A. Levitzki Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics J Biol Chem 278 2003 40442 40454
130. G. Blum, A. Gazit, and A. Levitzki Substrate competitive inhibitors of IGF-1 receptor kinase Biochemistry 39 2000 15705 15712
131. M. Parrizas, A. Gazit, A. Levitzki, E. Wertheimer, and D. LeRoith Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins Endocrinology 138 1997 1427 1433
132. M.J. Dirx, M.P. Zeegers, P.C. Dagnelie, T. van den Bogaard, and P.A. van den Brandt Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis Int J Cancer 106 2003 766 770
133. M.H. Ross, and G. Bras Lasting influence of early caloric restriction on prevalence of neoplasms in the rat J Natl Cancer Inst 47 1971 1095 1113
134. M.J. Dirx, P.A. van den Brandt, R.A. Goldbohm, and L.H. Lumey Diet in adolescence and the risk of breast cancer: results of the Netherlands Cohort Study Cancer Causes Control 10 1999 189 199
135. P.A. van Noord Breast cancer and the brain: a neurodevelopmental hypothesis to explain the opposing effects of caloric deprivation during the Dutch famine of 1944-1945 on breast cancer and its risk factors J Nutr 134 2004 3399S 3406S
136. F. de Waard, H.J. Collette, J.J. Rombach, E.A. Baanders-van Halewijn, and C. Honing The DOM project for the early detection of breast cancer, Utrecht, The Netherlands J Chronic Dis 37 1984 1 44
137. L.J. Hofland, and S.W. Lamberts Somatostatin receptors in pituitary function, diagnosis and therapy Front Horm Res 32 2004 235 252
138. M.N. Pollak, and A.V. Schally Mechanisms of antineoplastic action of somatostatin analogs Proc Soc Exp Biol Med 217 1998 143 152
139. Z. Szereday, A.V. Schally, and K. Szepeshazi Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238 Int J Oncol 22 2003 1141 1146
140. H. Kiaris, M. Koutsilieris, A. Kalofoutis, and A.V. Schally Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists Expert Opin Investig Drugs 12 2003 1385 1394
141. Z. Szereday, A.V. Schally, and J.L. Varga Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma Cancer Res 63 2003 7913 7919
142. J.J. Kopchick, C. Parkinson, E.C. Stevens, and P.J. Trainer Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly Endocr Rev 23 2002 623 646
143. M.S. Weber, P.L. Boyle, B.A. Corl, E.A. Wong, F.C. Gwazdauskas, and R.M. Akers Expression of ovine insulin-like growth factor-1 (IGF-1) stimulates alveolar bud development in mammary glands of transgenic mice Endocrine 8 1998 251 259
144. M.K. Dyck, A.F. Parlow, J.F. Senechal, M.A. Sirard, and F. Pothier Ovarian expression of human insulin-like growth factor-I in transgenic mice results in cyst formation Mol Reprod Dev 59 2001 178 185
145. D.L. Hadsell, N.M. Greenberg, J.M. Fligger, C.R. Baumrucker, and J.M. Rosen Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression Endocrinology 137 1996 321 330
146. S. Neuenschwander, A. Schwartz, T.L. Wood, C.T. Roberts Jr., L. Hennighausen, and D. LeRoith Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model J Clin Invest 97 1996 2225 2232
147. D.K. Bol, K. Kiguchi, I. Gimenez-Conti, T. Rupp, and J. DiGiovanni Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice Oncogene 14 1997 1725 1734
148. T.M. DeChiara, A. Efstratiadis, and E.J. Robertson A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting Nature 345 1990 78 80
149. C.E. Rogler, D. Yang, and L. Rossetti Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice J Biol Chem 269 1994 13779 13784
150. A. Ward, P. Bates, R. Fisher, L. Richardson, and C.F. Graham Disproportionate growth in mice with Igf-2 transgenes Proc Natl Acad Sci USA 91 1994 10365 10369
151. P. Bates, R. Fisher, A. Ward, L. Richardson, D.J. Hill, and C.F. Graham Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) Br J Cancer 72 1995 1189 1193
152. S.C. van Buul-Offers, K. de Haan, and M.G. Reijnen-Gresnigt Overexpression of human insulin-like growth factor-II in transgenic mice causes increased growth of the thymus J Endocrinol 144 1995 491 502
153. E. Wolf, R. Kramer, W.F. Blum, J. Foll, and G. Brem Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth Endocrinology 135 1994 1877 1886
154. G. Christofori, P. Naik, and D. Hanahan A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis Nature 369 1994 414 418